Replies to post #110617 on Regen BioPharma Inc (RGBP)

[Max2121]

I had misspelling of certain things in my previous postings.
Please read for accuracy of infos from 10-Q which was filled today.

[Here Today]

No word (Expense) in actual files 10Q from Page 37:

Material Changes in Results of Operations

Revenues from continuing operations were $58,717 for the quarter ended June 30, 2022 and $56,631 for the same period ended 2021.Operating Loss was $58,910 for the quarter ended June 30, 2022 as opposed to an Operating Loss of $42,491 recognized during the same quarter ended 2021. The increase in Operating Loss of 39% is primarily attributable to increased Research and Development, Consulting and Rental expenses recognized during the quarter ended June 30, 2022 as compared to the same period ended 2021.

The Company recognized Net Income of $66,958,167 during the quarter ended June 30, 2022 whereas a Net Loss of $7,489,114 was recognized during the same period ended 2021. This is primarily attributable to Derivative Income being recognized during the quarter ended 2022 as opposed to Derivative Losses recognized during the same period ended 2021.

Revenues from continuing operations were $176,151 for the nine months ended June 30, 2022 and $111,480 for the same period ended 2021.Operating Loss was $241,827 for the nine months ended June 30, 2022 as opposed to an Operating Loss of $73,945 recognized during the same quarter ended 2021. The increase in Operating Loss of 227% is primarily attributable to increased Research and Development, Consulting and Rental expenses recognized during the nine months ended June 30, 2022 as compared to the same period ended 2021.

The Company recognized Net Income of $2,521,557 during the nine months ended June 30, 2022 whereas a Net Loss of $5,380,566 was recognized during the same period ended 2021. This is primarily attributable to Derivative Income being recognized during the nine months ended 2022 as opposed to Derivative Losses recognized during the same period ended 2021.